Anti-p53 [Pab 240]
Invented by David Lane from Karolinska Institutet
Invented at Cancer Research UK London Research Institute: Clare Hall Laboratories
- Datasheet
- References (22)
- Inventor Info
Info
| Catalogue Number | 151146 |
| Applications | FACS IHC IF IP WB |
| Antigen/Gene or Protein Targets | p53 |
| Reactivity | Chicken and Mammalian |
| Relevance |
Monoclonal antibody reacts specifically with mutated p53 at an epitope conserved across species and normally hidden within the protein structure in non-mutant forms. Background and Research Application Anti-p53 (Pab 240) antibody recognises an evolutionary conserved epitope upon p53 hidden within the normal protein structure, however it does not bind to immunoprecipitated wild type p53. This antibody recognises an epitope which is structurally elusive when p53 is in a wildtype conformation but becomes accessible upon denaturation or through mutational conformations where point mutations within the TP53 gene alter the conformational structure of the protein. p53 is a stress-regulated transcription factor that regulates cell cycle arrest and was first identified as an SV40 large T antigen-binding protein. p53 is the most common genetic mutational event in so far identified in human cancers, with the gene present on the short arm of chromosome 17 – a frequent site of allele loss in common cancers. The structure of p53 comprises an N-terminal transactivation domain, a central DNA-binding domain, an oligomerisation domain, and a C-terminal regulatory domain. p53 is a tumour suppressor which upregulates growth arrest and apoptosis-related genes in response to stress signals, thereby influencing programmed cell death, cell differentiation, and cell cycle control mechanisms. Anti-p53 Pab 240 was created further understand the biochemical role of p53 in cancers and the precise effects of mutation. |
| Host | Mouse |
| Immunogen | A gel purified p53-b-galactosidase fusion protein containing p53 sequence from amino acids 14-389 (derived from the pSV53C p53 cDNA clone) |
| Immunogen UniProt ID | P04637 |
| Positive Control | MDA-MB-231 cell line |
| Subclass | IgG1 kappa |
| Molecular Weight (kDa) | 53 |
| Myeloma Used | Sp2/0-Ag14 |
| Recommended Growing Conditions | RPMI 1640 + 7.5% FCS |
| Strain | Balb/c |
| Notes |
Production Details Purified using multi-step affinity chromatography with protein A. Storage Conditions Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles. Points of Interest Detection of p53 using PAb 240: 50% colon cancer sections are positive, 30% of breast cancer sections and 70% of lung cancer sections. Normal and premalignant tissue are negative. Immunoprecipitation with anti-p53 Pab 240 is a possible diagnostic for mutation within p53. It is thought that different point mutations which convert p53 from a recessive to a dominant oncogene exert a common conformational effect to the protein, which prevents (SV40) T antigen binding and promotes self-oligomerisation. Anti-p53 Pab 240 cannot bind to p53 when it is bound to SV40 T antigen. p53 must be unfolded or ‘melted’ from its normal 3D structure, as in most p53 mutants, to react with Pab240. This antibody was selected for further study given it reacts with human, mouse, rat, hamster, bovine and chicken p53 in immunoblotting experiments. It can stain both the nuclei and cytoplasm, a key indicator of the presence of mutant p53 as typically wild-type p53 is only present within the nucleus. Concentration 1mg/ml as standard Difference Between Clones Pab 246 binds to wild type p53, whereas pab240 binds to mutated or denatured p53. |
| Research Area | Apoptosis and Programmed Cell Death, Cancer, Cell Cycle, DNA Damage and Repair, Epigenetics & Nuclear Signalling |
References: 22 entries
Renzi et al. 2019. PLoS One. 14(4):e0215621. PMID: 30998743.
Diaz Osterman et al. 2019. Elife. 8:. PMID: 31478830.
Fekry et al. 2018. Nat Commun. 9(1):4149. PMID: 30297838.
Katz et al. 2018. Genes Dev. 32(5-6):430-447. PMID: 29549180.
Chen et al. 2017. Br J Pharmacol. 174(23):4345-4361. PMID: 28910492.
İlhan et al. 2016. J Vet Diagn Invest. :. PMID: 27016721.
Expression of p53 protein, Jaagsiekte sheep retrovirus matrix protein, and surfactant protein in the lungs of sheep with pulmonary adenomatosis.
Europe PMC ID: 27016721
Jakobsen et al. 2015. J Extracell Vesicles. 4:26659. PMID: 25735706.
Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.
Europe PMC ID: 25735706
Pan et al. 2009. EMBO J. 28(22):3500-13. PMID: 19745809.
SnoN functions as a tumour suppressor by inducing premature senescence.
Europe PMC ID: 19745809
Said et al. 1992. Am J Pathol. 141(6):1343-8. PMID: 1466398.
Immunohistochemical analysis of p53 expression in malignant lymphomas.
Europe PMC ID: 1466398
Walker et al. 1991. J Pathol. 165(3):203-11. PMID: 1684809.
Expression of p53 protein in infiltrating and in-situ breast carcinomas.
Europe PMC ID: 1684809
Bártek et al. 1991. Oncogene. 6(9):1699-703. PMID: 1923535.
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.
Europe PMC ID: 1923535
Gannon et al. 1990. EMBO J. 9(5):1595-602. PMID: 1691710.
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
Europe PMC ID: 1691710
Iggo et al. 1990. Lancet. 335(8691):675-9. PMID: 1969059.
Increased expression of mutant forms of p53 oncogene in primary lung cancer.
Europe PMC ID: 1969059
Greaves. R. F (1988) Ph.D Thesis. University of London.
Add a reference
References: 22 entries
Renzi et al. 2019. PLoS One. 14(4):e0215621. PMID: 30998743.
Diaz Osterman et al. 2019. Elife. 8:. PMID: 31478830.
Fekry et al. 2018. Nat Commun. 9(1):4149. PMID: 30297838.
Katz et al. 2018. Genes Dev. 32(5-6):430-447. PMID: 29549180.
Chen et al. 2017. Br J Pharmacol. 174(23):4345-4361. PMID: 28910492.
İlhan et al. 2016. J Vet Diagn Invest. :. PMID: 27016721.
Expression of p53 protein, Jaagsiekte sheep retrovirus matrix protein, and surfactant protein in the lungs of sheep with pulmonary adenomatosis.
Jakobsen et al. 2015. J Extracell Vesicles. 4:26659. PMID: 25735706.
Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.
Pan et al. 2009. EMBO J. 28(22):3500-13. PMID: 19745809.
SnoN functions as a tumour suppressor by inducing premature senescence.
Said et al. 1992. Am J Pathol. 141(6):1343-8. PMID: 1466398.
Immunohistochemical analysis of p53 expression in malignant lymphomas.
Walker et al. 1991. J Pathol. 165(3):203-11. PMID: 1684809.
Expression of p53 protein in infiltrating and in-situ breast carcinomas.
Bártek et al. 1991. Oncogene. 6(9):1699-703. PMID: 1923535.
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.
Gannon et al. 1990. EMBO J. 9(5):1595-602. PMID: 1691710.
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
Iggo et al. 1990. Lancet. 335(8691):675-9. PMID: 1969059.
Increased expression of mutant forms of p53 oncogene in primary lung cancer.
Greaves. R. F (1988) Ph.D Thesis. University of London.
Add a reference
